Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline.
Neion Bio
Private
Neion Bio is a private biomanufacturing platform company using transgenic chicken eggs to produce recombinant proteins at scale. The company's ovum-based expression system promises faster, cheaper production of complex biologics compared to traditional mammalian cell culture.
Company Info
Sector:Biotechnology / Biomanufacturing
Headquarters:San Diego, California, USA
Founded:2022
Website:www.neionbio.com/
Funding Round:Series A June 2026 ($23M)
Total Funding:$30M+ (cumulative)
Funding & Investor Relations
Notable Investors
- Khosla Ventures
- ARCH Venture Partners
- Y Combinator
- Codon Capital
- RA Capital Management
IPO Outlook / Plans
None publicly disclosed; pre-commercial biomanufacturing platform company.
Upcoming Milestones & Key Dates
Late 2026
Manufacturing
GMP-scale pilot launch for NB-001 enzyme product
Q1 2027
Business Development
First commercial partnerships for egg-based biologics platform
Clinical Development Pipeline
NB-001 (proprietary enzyme)
Target: Recombinant protein expressed in chicken egg whitesNB-002 (cytokine biologic)
Target: Recombinant interleukin expressed in eggsNB-101 (vaccine antigen)
Target: Recombinant hemagglutinin antigenRecent News
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline.
Leadership Team
Careers & Job Openings